-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Parkman Healthcare Partners LLC Raises Stock Holdings in Imago BioSciences, Inc. (NASDAQ:IMGO)
Parkman Healthcare Partners LLC Raises Stock Holdings in Imago BioSciences, Inc. (NASDAQ:IMGO)
Parkman Healthcare Partners LLC lifted its holdings in shares of Imago BioSciences, Inc. (NASDAQ:IMGO – Get Rating) by 27.0% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 139,751 shares of the company's stock after purchasing an additional 29,751 shares during the quarter. Parkman Healthcare Partners LLC's holdings in Imago BioSciences were worth $2,693,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently modified their holdings of the business. Vanguard Group Inc. grew its holdings in shares of Imago BioSciences by 68.8% during the first quarter. Vanguard Group Inc. now owns 793,101 shares of the company's stock worth $15,283,000 after purchasing an additional 323,376 shares in the last quarter. BlackRock Inc. lifted its position in Imago BioSciences by 146.2% in the 1st quarter. BlackRock Inc. now owns 3,290,894 shares of the company's stock worth $63,415,000 after buying an additional 1,954,112 shares during the last quarter. Rhumbline Advisers bought a new stake in Imago BioSciences in the 1st quarter worth approximately $345,000. Metropolitan Life Insurance Co NY bought a new stake in Imago BioSciences in the 1st quarter worth approximately $28,000. Finally, MetLife Investment Management LLC bought a new stake in Imago BioSciences in the first quarter valued at approximately $242,000. Hedge funds and other institutional investors own 99.50% of the company's stock.
Get Imago BioSciences alerts:Insider Transactions at Imago BioSciences
In other news, insider Jennifer Peppe sold 5,598 shares of the stock in a transaction on Monday, August 15th. The stock was sold at an average price of $19.41, for a total value of $108,657.18. Following the sale, the insider now directly owns 148,809 shares of the company's stock, valued at $2,888,382.69. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Over the last three months, insiders have sold 8,168 shares of company stock valued at $155,402. Insiders own 14.90% of the company's stock.
Analyst Ratings Changes
Separately, HC Wainwright reduced their target price on Imago BioSciences from $36.00 to $35.00 and set a "buy" rating on the stock in a research note on Tuesday, August 16th.Imago BioSciences Price Performance
NASDAQ IMGO opened at $16.77 on Friday. Imago BioSciences, Inc. has a 12 month low of $11.56 and a 12 month high of $30.21. The stock's fifty day moving average price is $16.32 and its 200-day moving average price is $17.09.
About Imago BioSciences
(Get Rating)
Imago BioSciences, Inc, a clinical stage biopharmaceutical company, discovers and develops small molecule product candidates that target lysine-specific demethylase 1(LSD1), an enzyme that used in the production of blood cells in the bone marrow. Its lead product candidate is bomedemstat, which is in Phase II clinical trials for the treatment of myeloproliferative neoplasms chronic cancers of the bone marrow, such as myelofibrosis, essential thrombocythemia, and polycythemia vera.
See Also
- Get a free copy of the StockNews.com research report on Imago BioSciences (IMGO)
- Prepare For A Record-Setting Quarter For Cyber Security Stocks
- The Auto Market Is Slowly Recovering, These Stocks May Outperform
- Is DocuSign On The Verge Of A Major Reversal?
- Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy
- Are These Green Energy Companies Right For Your Portfolio?
Want to see what other hedge funds are holding IMGO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Imago BioSciences, Inc. (NASDAQ:IMGO – Get Rating).
Receive News & Ratings for Imago BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imago BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.
Parkman Healthcare Partners LLC lifted its holdings in shares of Imago BioSciences, Inc. (NASDAQ:IMGO – Get Rating) by 27.0% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 139,751 shares of the company's stock after purchasing an additional 29,751 shares during the quarter. Parkman Healthcare Partners LLC's holdings in Imago BioSciences were worth $2,693,000 at the end of the most recent quarter.
根據Parkman Healthcare Partners LLC提交給美國證券交易委員會的最新Form 13F文件,該公司在第一季度增持了Imago BioSciences,Inc.(納斯達克代碼:IMGO-GET評級)的股票27.0%。該機構投資者在本季度額外購買了29,751股後,持有該公司139,751股股票。截至最近一個季度末,Parkman Healthcare Partners LLC持有的Imago BioSciences股份價值2,693,000美元。
Several other hedge funds and other institutional investors also recently modified their holdings of the business. Vanguard Group Inc. grew its holdings in shares of Imago BioSciences by 68.8% during the first quarter. Vanguard Group Inc. now owns 793,101 shares of the company's stock worth $15,283,000 after purchasing an additional 323,376 shares in the last quarter. BlackRock Inc. lifted its position in Imago BioSciences by 146.2% in the 1st quarter. BlackRock Inc. now owns 3,290,894 shares of the company's stock worth $63,415,000 after buying an additional 1,954,112 shares during the last quarter. Rhumbline Advisers bought a new stake in Imago BioSciences in the 1st quarter worth approximately $345,000. Metropolitan Life Insurance Co NY bought a new stake in Imago BioSciences in the 1st quarter worth approximately $28,000. Finally, MetLife Investment Management LLC bought a new stake in Imago BioSciences in the first quarter valued at approximately $242,000. Hedge funds and other institutional investors own 99.50% of the company's stock.
其他幾家對衝基金和其他機構投資者最近也調整了對該公司的持股。先鋒集團(Vanguard Group Inc.)在第一季度增持了Imago BioSciences股票68.8%。先鋒集團目前持有793,101股該公司股票,價值15,283,000美元,上個季度又購買了323,376股。第一季度,貝萊德公司將其在Imago BioSciences的地位提升了146.2%。貝萊德股份有限公司在上個季度增持了1,954,112股後,目前持有該公司3,290,894股股票,價值63,415,000美元。Rhumbline Advisers在第一季度購買了Imago BioSciences的新股份,價值約34.5萬美元。紐約大都會人壽保險公司在第一季度購買了Imago BioSciences的新股份,價值約2.8萬美元。最後,大都會人壽投資管理有限責任公司在第一季度購買了Imago BioSciences的新股份,價值約為242,000美元。對衝基金和其他機構投資者持有該公司99.50%的股票。
Insider Transactions at Imago BioSciences
Imago BioSciences的內幕交易
In other news, insider Jennifer Peppe sold 5,598 shares of the stock in a transaction on Monday, August 15th. The stock was sold at an average price of $19.41, for a total value of $108,657.18. Following the sale, the insider now directly owns 148,809 shares of the company's stock, valued at $2,888,382.69. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Over the last three months, insiders have sold 8,168 shares of company stock valued at $155,402. Insiders own 14.90% of the company's stock.
其他消息,內部人士珍妮弗·佩佩在8月15日(星期一)的一次交易中出售了5598股該股。這隻股票的平均售價為19.41美元,總價值為108,657.18美元。出售後,這位內部人士現在直接持有該公司148,809股股票,價值2,888,382.69美元。這筆交易是在提交給美國證券交易委員會的一份法律文件中披露的,可以通過這個超級鏈接獲得。在過去的三個月裏,內部人士出售了8,168股公司股票,價值155,402美元。內部人士持有該公司14.90%的股份。
Analyst Ratings Changes
分析師評級發生變化
Imago BioSciences Price Performance
Imago BioSciences性價比
NASDAQ IMGO opened at $16.77 on Friday. Imago BioSciences, Inc. has a 12 month low of $11.56 and a 12 month high of $30.21. The stock's fifty day moving average price is $16.32 and its 200-day moving average price is $17.09.
納斯達克IMGO上週五開盤報16.77美元。Imago BioSciences,Inc.的12個月低點為11.56美元,12個月高位為30.21美元。該股的50日移動均線價格為16.32美元,200日移動均線價格為17.09美元。
About Imago BioSciences
關於Imago BioSciences
(Get Rating)
(獲取評級)
Imago BioSciences, Inc, a clinical stage biopharmaceutical company, discovers and develops small molecule product candidates that target lysine-specific demethylase 1(LSD1), an enzyme that used in the production of blood cells in the bone marrow. Its lead product candidate is bomedemstat, which is in Phase II clinical trials for the treatment of myeloproliferative neoplasms chronic cancers of the bone marrow, such as myelofibrosis, essential thrombocythemia, and polycythemia vera.
臨牀階段生物製藥公司Imago BioSciences,Inc.發現和開發了針對賴氨酸特異性脱甲基酶1(LSD1)的小分子產品候選產品,LSD1是一種用於生產骨髓中血細胞的酶。它的主要候選產品是Bomedemstat,正在進行第二階段臨牀試驗,用於治療骨髓增生性腫瘤和慢性骨髓癌,如骨髓纖維化、原發性血小板增多症和真性紅細胞增多症。
See Also
另請參閲
- Get a free copy of the StockNews.com research report on Imago BioSciences (IMGO)
- Prepare For A Record-Setting Quarter For Cyber Security Stocks
- The Auto Market Is Slowly Recovering, These Stocks May Outperform
- Is DocuSign On The Verge Of A Major Reversal?
- Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy
- Are These Green Energy Companies Right For Your Portfolio?
- 免費獲取StockNews.com關於Imago BioSciences(IMGO)的研究報告
- 為網絡安全股創紀錄的季度做準備
- 汽車市場正在緩慢復甦,這些股票可能表現優異
- DocuSign是否即將發生重大逆轉?
- 石油和天然氣股票:投資可再生能源的安全途徑
- 這些綠色能源公司適合你的投資組合嗎?
Want to see what other hedge funds are holding IMGO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Imago BioSciences, Inc. (NASDAQ:IMGO – Get Rating).
想看看其他對衝基金持有IMGO的股票嗎?訪問HoldingsChannel.com獲取Imago BioSciences,Inc.(納斯達克代碼:IMGO-GET Rating)的最新13F申報文件和內幕交易信息。
Receive News & Ratings for Imago BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imago BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.
接受Imago生物科學日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Imago BioSciences和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧